Month: January 2024

All amounts shown in this press release are in United States dollars unless otherwise indicated WINNIPEG, Manitoba, Jan. 17, 2024 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI” or the “Company”), a leading independent global bus and coach manufacturer and a leader in electric mass mobility solutions, provided an update on its deliveries for the 13-week period ended December 31, 2023 (“2023 Q4”), and provided an update on its orders, backlog1 and financial guidance as of the end of 2023 Q4.2 All figures related to 2023 Q4 and Fiscal 2023 included in this press release are unaudited and will be finalized prior to the release of NFI’s audited financial results. “NFI finished 2023 strong as our team delivered buses, coaches, and aftermarket parts in line with our expectations,” said Paul Soubry,...

BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Sequire Investor Summit 2024, which is planned for January 23-25, 2024, at Condado Vanderbilt Hotel in San Juan, Puerto Rico. Details of the event are as follows:Event: Sequire Investor Summit 2024Date:  January 23-25, 2024Presentation January 24, 10:30 AM AST, Track 3 (Salon Azul)Location: Condado Vanderbilt Hotel in San Juan, Puerto RicoRegistration: https://puertorico.srax.com/During the conference, members of the First Wave BioPharma...

BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointment of Mary Beth DeLena as General Counsel and Secretary. Ms. DeLena joins PepGen with over 20 years of experience advising global life science companies in a broad range of strategic, transactional, and corporate matters with extensive experience in business development, finance, securities, corporate governance, employment and commercial law. Prior to PepGen, Mary Beth spent 15 years at Alnylam Pharmaceuticals in roles of increasing responsibility, most recently serving as Senior Vice President, Deputy...

NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) — LXP Industrial Trust (NYSE:LXP) (“LXP”), a real estate investment trust (REIT) focused on single-tenant warehouse and distribution real estate investments, today announced it will release its fourth quarter 2023 financial results the morning of Thursday, February 15, 2024. LXP will host its conference call and webcast that same day at 8:30 a.m., Eastern Time to discuss these results. Participants may access the call and webcast by the following: Conference Call: (888) 660-6082 or (929) 201-6604Conference ID: 1576583Webcast: https://events.q4inc.com/attendee/297946487or visit: https://ir.lxp.com/events-and-presentations/events/default.aspx to access webcast link A telephone replay of the call will be available through May 15, 2024 and via webcast for one year by accessing: Telephone: (800)...

Updates fourth quarter revenue guidance to $165 to $175 million & Non-GAAP diluted EPS between $0.40 to $0.45 cents Initial 2024 revenue outlook of $680 to $740 million & Non-GAAP diluted EPS outlook between $1.60 to $1.90 Veeco to participate at upcoming 26th Annual Needham Growth ConferencePLAINVIEW, N.Y., Jan. 17, 2024 (GLOBE NEWSWIRE) — Veeco Instruments Inc. (NASDAQ: VECO) today has updated its financial guidance for the fourth quarter of 2023 and provided an initial 2024 outlook. Veeco’s management is scheduled to meet with investors and present at the 26th Annual Needham Growth Conference later today, where they will discuss Veeco’s updated 2023 guidance and provide an initial 2024 outlook. The presentation will be broadcast live at 11:45 AM ET and can be accessed on the investor relations section of Veeco’s...

MELBOURNE, Australia and NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that an independent Institutional Review Board (IRB) has approved the protocol for the Company’s Phase 2/3 clinical trial to be conducted in the United States to assess safety and efficacy of proprietary combination drug candidate IHL-42X in patients with obstructive sleep apnea (OSA). IRB approval of the protocol is a key step in activation of clinical trial sites for the RePOSA study. Under regulations of the Food & Drug Administration, IRB approval is required prior to commencing research in human subjects and serves to ensure that appropriate...

TORONTO, Jan. 17, 2024 (GLOBE NEWSWIRE) — HydroGraph Clean Power Inc. (CSE: HG) (OTCBQ: HGCPF) (the “Company” or “HydroGraph”), a manufacturer of pristine graphene, today issued the following letter to its stakeholders from HydroGraph CEO Stuart Jara. Dear HydroGraph Stakeholders, Colleagues and Friends: Reflecting on 2023, I am incredibly proud of the significant progress HydroGraph has made to position us squarely on the path to secure our first major customer contracts. We have achieved key operational milestones, advanced our application development and established new commercial and strategic partnerships, despite the challenging macroeconomic and geopolitical environments. On the foundation of the progress made in 2023, the goals set for 2024 should position us to secure the first significant contract in 2024. We will also...

CERVAI™ Brain HealthCERVAI™ Brain HealthTORONTO, Jan. 17, 2024 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health artificial intelligence company focused on brain health, today announced the pilot launch of CERVAI™, a world-first consumer brain health and wellness AI solution that aims to ‘raise a red flag’ for potential brain health issues by estimating brain age and providing a brain health score. Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “After over two years in development, CERVAI™, a world-first consumer brain health and wellness solution that estimates brain age and provides a brain health score, is available to clinics seeking to provide a unique service that helps bridge the gaps in physical and cognitive...

GURU Organic EnergyGURU’s punch lineup: Peach Mango Punch, Tropical Punch and Fruit PunchPeach Mango Punch offers an amazing flavor explosion, with GURU’s unique blend of natural ingredients to increase focus and brain performance. Newest addition to punch line, Peach Mango Punch, and recently launched Fruit Punch, will both be available to US retailers starting in February. GURU’s entire punch lineup, consisting of Tropical Punch, Fruit Punch and Peach Mango Punch, will also be showcased to US retailers at TheFitExpo, KeHE, UNFI, and Expo West trade shows.MONTRÉAL, Jan. 17, 2024 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company”), Canada’s leading organic energy drink brand1, today announced the launch of its new Peach Mango Punch in the US, available on Amazon.com and directly on the...